Clinical outcomes after multilesion percutaneous coronary intervention: Comparison between exclusive and selective use of drug-eluting stents

Journal of Invasive Cardiology

Volumn 20, Issue 3, 2008, Pages 99-104

  Bertrand, Olivier F ^a,b   Faurie, Benjamin ^a   Larose, Éric ^a   Nguyen, Can Manh ^a   Gleeton, Onil ^a   Déry, Jean Pierre ^a   Noël, Bernard ^a   Proulx, Guy ^a   Roy, Louis ^a   Costerousse, Olivier ^a   De Larochellière, Robert ^a   Rodés Cabau, Josep ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Coronary; Multi lesions; Radial; Stent; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PACLITAXEL; RAPAMYCIN;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BARE METAL STENT; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DEATH; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HAZARD RATIO; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; REVASCULARIZATION; SCORING SYSTEM; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; QUEBEC; RETROSPECTIVE STUDIES; STENTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 40449088893     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 Trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-1039.
2. Ong AT, Serruys PW, Aoki J, et al. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: One-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 2005;45:1135-1141.
3. Saia F, Piovaccari G, Manari A, et al. Clinical outcomes for sirolimus-eluting stents and polymer-coated paclitaxel-eluting stents in daily practice: Results from a large multicenter registry. J Am Coll Cardiol 2006;48:1312-1318.
4. Ong AT, Daemen J, van Hout BA, et al. Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: Results from the RESEARCH Registry. Eur Heart J 2006;27:2996-3003.
5. Lagerqvist B, James SK, Stenestrand U, et al. Long-Term Outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-1019.
6. Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:989-997.
7. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
8. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: A cause for concern. Circulation 2007;115:1440-1455.
9. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-2591.
10. Kaiser C, Brunner-La Rocca HP, Buser PT, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: Randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005;366:921-929.
11. Fineschi M, Gori T, Pierli C, et al. Outcome of percutaneous hybrid coronary revascularization: Bare metal stents jeopardize the benefit of sirolimus-eluting stents in the real world. Can J Cardiol 2005;21:1281-1285.
12. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-1029.
13. Bagust A, Grayson AD, Palmer ND, et al. Cost effectiveness of drug eluting coronary artery stenting in a UK setting: Cost-utility study. Heart 2006;92:68-74.
14. Brophy JM, Erickson LJ. Cost-effectiveness of drug-eluting coronary stents in Quebec, Canada. Int J Technol Assess Health Care 2005;21:326-333.
15. Ligthart S, Vlemmix F, Dendukuri N, Brophy JM. The cost-effectiveness of drug-eluting stents: A systematic review. CMAJ 2007;176:199-205.
16. Marzocchi A, Piovaccari G, Manari A, et al. Comparison of effectiveness of sirolimus-eluting stents versus bare metal stents for percutaneous coronary intervention in patients at high risk for coronary restenosis or clinical adverse events. Am J Cardiol 2005;95:1409-1414.
17. Shrive FM, Manns BJ, Galbraith PD, et al. Economic evaluation of sirolimus-eluting stents. CMAJ 2005;172:345-351.
18. Farb A, Boam AB. Stent thrombosis redux - The FDA perspective. N Engl J Med 2007;356:984-987.
19. Chu WW, Rha SW, Kuchulakanti PK, et al. Selective versus exclusive use of sirolimus-eluting stent implantation in multivessel coronary artery disease. Catheter Cardiovasc Interv 2005;65:473-477.
20. Roy P, Yan B, Warren R. The clinical outcome of restricting drug-eluting stents to patients at highest risk of restenosis. Euro Interv 2006;2:238-243.
21. Cardiac Care Network (CCN) of Ontario. Working group on drug eluting stents report on initial utilization strategy. Final report and recommendations. Toronto:CCN;2003, available at http://www.ccn.on.ca/publications/ finaldrugelutingmaster2_Dec2002.pdf..
22. Réseau Québécois de Cardiologie Tertiaire (RQCT). Avis sur l'utilisation des tuteurs médicamentés à l'intention du ministre de la santé et des services sociaux. 2003. First published in July 2003 and updated 2004.
23. Lima VC, Mattos LA, Caramori PR, et al. Expert consensus (SBC/SBHCI) on the use of drug-eluting stents: Recommendations of the Brazilian society of interventional cardiology/Brazilian society of cardiology for the Brazilian public single healthcare system. Arq Bras Cardiol 2006;87:e162-e167.
24. Lord SJ, Howard K, Allen F, et al. A systematic review and economic analysis of drug-eluting coronary stents available in Australia. Med J Aust 2005;183:464-471.
25. Hill R, Bagust A, Bakhai A, et al. Coronary artery stents: A rapid systematic review and economic evaluation. Health Technol Assess 2004;8:iii-iv,1-242.
26. Oliva G. Cost-effectiveness of drug-eluting stents: Implications for clinical practice and healthcare costs. Rev Esp Cardiol 2006;59:865-868.
27. Pache J, Dibra A, Mehilli J, et al. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: A prospective, randomized trial. Eur Heart J 2005;26:1262-1268.
28. Yock C, Isbill J, King S. Bare-metal stent outcomes in an unselected patient population. Clin Cardiol 2006;29:352-356.